Form 4: Whitehawk Therapeutics CFO Acquires Shares

Scott M. Giacobello, Chief Financial Officer of Whitehawk Therapeutics, Inc., acquired 38,265 shares of common stock on May 14, 2026.

Summary

• Scott M. Giacobello, Chief Financial Officer of Whitehawk Therapeutics, Inc., acquired 38,265 shares of common stock on May 14, 2026.
• The acquisition was made at a price of $3.92 per share.
• Following this transaction, Mr. Giacobello beneficially owns 333,489 shares of common stock.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive filing due to the insider purchase by the CFO, which can indicate confidence, but lacks broader financial or strategic information.

Positives

• Insider buying can signal confidence in the company's future prospects.
• The CFO's acquisition of a significant number of shares may be interpreted positively by the market.

Future Outlook

No forward-looking statements or guidance are present in this filing.

Industry Context

StockSavvy.ai notes that insider transactions, particularly by C-suite executives like a CFO, are closely watched by investors as they can provide insights into management's perception of the company's valuation and future performance. This acquisition by the CFO of Whitehawk Therapeutics could be interpreted as a positive signal.

Stakeholder Impact

• Shareholders may view the CFO's purchase as a positive signal of confidence in the company's future.

Key Dates

Recommendation

The filing reports an insider purchase by the CFO, which is generally a positive indicator. However, without additional context on the company's financial performance, strategic initiatives, or broader market conditions, a 'hold' recommendation is prudent, suggesting investors monitor further developments.

Keywords

Whitehawk Therapeutics, WHWK, Form 4, Insider Transaction, Stock Acquisition, CFO, Beneficial Ownership